Evidence map›Paper›PMID 34146099›Full record

ArticleRheumatology (Oxford, England)2021

Impact of the COVID-19 pandemic on treat-to-target strategies and physical consultations in >7000 patients with inflammatory arthritis.

Bente Glintborg, Dorte Vendelbo Jensen, Lene Terslev, Mogens Pfeiffer Jensen, Oliver Hendricks, Mikkel Østergaard, Sara Engel, Simon Horskjær Rasmussen, Thomas Adelsten, Ada Colic and 11 more

Abstract read
In one paragraph

Article in Rheumatology (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Bente GlintborgDANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Denmark.ORCID 0000-0002-8931-8482
Dorte Vendelbo JensenDANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Denmark.
Lene TerslevDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID 0000-0001-8193-9471
Mogens Pfeiffer JensenDepartment of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Oliver HendricksDanish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark.
Mikkel ØstergaardDANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Denmark.
Sara EngelDANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Denmark.
Simon Horskjær RasmussenCopenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark.
Thomas AdelstenDepartment of Rheumatology, Zealand University Hospital, Køge, Denmark.
Ada ColicDepartment of Rheumatology, Zealand University Hospital, Køge, Denmark.
Kamilla DanebodDepartment of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark.
Malene KildemandDepartment of Rheumatology, Odense University Hospital, Odense, Denmark.
Anne Gitte LoftDepartment of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
Heidi Lausten MunkDepartment of Rheumatology, Odense University Hospital, Odense, Denmark.
Jens Kristian PedersenDepartment of Clinical Research, University of Southern Denmark, Odense, Denmark.ORCID 0000-0003-2531-9547
René Drage ØstgårdRheumatology Section, Department of Medicine M, Odense University Hospital and Svendborg Hospital, Svendborg, Denmark.
Christian Møller SørensenDepartment of Medicine, Horsens Regional Hospital, Horsens, Denmark.
Niels Steen KroghZitelab, Copenhagen, Denmark.
Jette Nørgaard AgerboGigtforeningen/Danish Rheumatism Association, Denmark.
Connie ZieglerGigtforeningen/Danish Rheumatism Association, Denmark.
Merete Lund HetlandDANBIO and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Denmark.

Funding

Lundbeck Foundation R349-2020-629
6 · The paper itself

Abstract

objectivesTo explore the impact of the COVID-19 pandemic on treat-to-target strategies (disease activity, remission rates) and access to physical consultations in patients with inflammatory rheumatic disease, as well as to explore characteristics of patients with/without physical consultations in the clinic and the impact of early vs established disease.

methodsPatients with RA, PsA or axial SpA (axSpA) prospectively followed in the nationwide DANBIO registry answered online questionnaires and reported patient-reported outcomes (PROs) in June and November 2020. Patient characteristics, disease activity and physical consultations in the clinic before and during the pandemic were identified in DANBIO [all patients and subgroups with early disease (disease duration ≤2 years)]. In individual patients, changes in PROs before and during the pandemic were calculated. Characteristics of patients with/without physical consultations were described (age, gender, education level, comorbidities, disease duration, treatment).

resultsWe included 7836 patients (22% of eligible patients), 12% of which had early disease. PROs were stable before and during the pandemic, with median changes approximating zero, as well as in patients with early disease. Remission rates were stable. The relative decrease in the number of patients with physical consultations was 21-72%, which was highest in axSpA. Characteristics of patients with/without physical consultations were similar. Self-reported satisfaction with treatment options and access was >70%; the preferred contact form was physical consultation (66%).

conclusionIn this nationwide study performed during the first 8 months of the pandemic, patient satisfaction was high and the PROs and remission rates remained stable despite the remarkable reduction in physical consultations, as well as in patients with early disease. Characteristics of patients with/without physical consultations appeared similar.

Indexed as

COVID-19AdultAgedArthritis, PsoriaticArthritis, RheumatoidDenmarkFemaleHealth Services AccessibilityHumansMaleMiddle AgedPatient Acceptance of Health CarePatient Reported Outcome MeasuresProspective StudiesReferral and ConsultationRegistriesaxial spondyloarthritisCOVID-19observational researchoutcome measuresRASARS-CoV-19treat-to-target

Identifiers

PMID34146099
PMCPMC8344418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.